DRUG · Mapped RxNorm record
Dolutegravir 50 MG
Normalized identity: dolutegravir 50 MGView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
NCT04340388
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Antiretroviral/Anti HIV
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedContribution of Dolutegravir to Obesity and Cardiovascular Disease
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HIV-1-infectionunresolved
Antiviral Drug Adverse Reactionunresolved
Vascular Diseasesunresolved
Cardiovascular Abnormalitiesunresolved
Abnormality of Adipose Tissueunresolved
Body Weight Changesunresolved
Body Fat Disorderunresolved
HIV-Associated Lipodystrophy Syndromeunresolved
Interventions
Dolutegravir 50 MGDRUG · verified · RxNorm: dolutegravir 50 MG
Sponsors & collaborators
Augusta Universitylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04340388 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.